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A B S T R A C T
Background: The burden of renal cell carcinoma (RCC) in young adults received marginal attention. We assessed
contemporary gender, race and stage-specific incidence and trends of RCC among young adults (20–39 years-
old) in the United States.
Methods: Within Surveillance, Epidemiology, and End Results database (2000–2016), patients aged 20–39 years
with histologically confirmed RCC were included. Age-standardized incidence rates (ASR per 100,000 person-
years) were estimated. Temporal trends were calculated through joinpoint regression analyses to describe the
average annual percent change (AAPC).
Results: From 2000–2016, 7767 new RCC cases were recorded (ASR 0.6, AAPC +5.0 %, p < 0.001). ASRs
were higher in males than in females (0.7 and 0.5, respectively) and increased significantly in both genders
(AAPC+5.0 % and +4.7 % both p < 0.001, respectively). Non-Hispanic American Indian/Alaska Native had
the highest incidence (ASR 1.0) vs. non-Hispanic Asian or Pacific Islander the lowest (ASR 0.3). ASRs sig-
nificantly increased in all ethnic groups. T1aN0M0 and T1bN0M0 stages showed the highest incidence and
increase (ASR 0.3, AAPC+5.9 %, p < 0.001 and ASR 0.1, AAPC+5.7 %, p < 0.001, respectively). Also
regional and distant stages increased (AAPC+3.7 %, p= 0.001 and AAPC+1.5 %, p= 0.06). The most fre-
quent tumor characteristics were G2 (44.4 %, ASR 0.3, AAPC+6.3 %, p < 0.001) and G1 (13.1 %, ASR 0.1,
AAPC+1.1 %, p= 0.2), as well as clear cell histology (54.8 %, ASR 0.3, AAPC +7.6 %, p < 0.001).
Conclusions: RCC in young adults is rare, but increasing. This is mainly due to T1aN0M0 tumors. Nonetheless,
also regional diseases are significantly increasing. Differences between ethnic groups exist and may warrant
further research.
https://doi.org/10.1016/j.canep.2020.101762
Received 25 February 2020; Received in revised form 27 May 2020
⁎ Corresponding author at: Urology Unit, ASST Spedali Civili of Brescia. Department of Medical and Surgical Specialties, Radiological Science and Public Health,
University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
E-mail address: palumbo.carlotta@gmail.com (C. Palumbo).
Cancer Epidemiology 67 (2020) 101762
1877-7821/ © 2020 Elsevier Ltd. All rights reserved.
T
1. Introduction
Renal cell carcinoma (RCC) represents the eighth (4.2 %) most
frequently diagnosed cancer, with 65,340 new cases estimated for year
2018 in the United States alone [1]. Recent data showed that North
America has the highest RCC incidence worldwide, with a cumulative
risk of respectively 1.8 % in males and 0.9 % in females [2]. Generally,
RCC is most frequently diagnosed between ages 65–74 years with less
than 9% of new cases diagnosed in patients younger than 45 years [1].
Nonetheless, cancer in young adults may be a cause of premature
morbidity with long-lasting health and socioeconomic effects. To date,
few studies large scale [3–6] addressed the topic of cancer burden in-
cidence among young adults. Despite the strengths of these studies,
more granular information on incidence according to race, stage and
tumor characteristics in young adults is needed. Indeed, more detailed
information only derived from institutional series [7–9] that however
did not report on incidence rates.
We hypothesized that most RCCs in young adults are diagnosed as
low risk cancers, which would confirm timely diagnosis. Nonetheless,
this may also imply over-diagnosis with risk of potential unnecessary
treatments and potential impairment of long-term kidney health. To
test these hypotheses, we assessed incidence rates of RCC in young
adults (20–39 years-old) in the United States, using the most recent
version of the SEER database (2000–2016). We reported on age-stan-
dardized incidence rates and trends over time in the overall population,
as well as after stratification according to gender, race, stage and tumor
characteristics.
2. Materials and methods
2.1. Data source and study population
The SEER Program covers approximately 34.6 % of the U.S. popu-
lation [10]. Within the SEER 18 registry database (2000–2016), we
focused on patients diagnosed with primary histologically confirmed
tumors of renal parenchyma (International Classification of Disease for
Oncology [ICD-O] site code C64.9). Young adults were defined as those
aged from 20–39 years, according to the definition of the Adolescent
and Young Adult Oncology Progress Review Group [11]. Autopsy and
death certificates only cases were excluded. This study followed SEER
reporting guidelines. In accordance to the anonymous nature of SEER,
no formal ethical approval was required.
Race was coded according to SEER race and origin code, as Hispanic
within all races, non-Hispanic White (NHW), non-Hispanic African-
American (NHAA), non-Hispanic American Indian/Alaska Native
(NHAIAN), non-Hispanic Asian or Pacific Islander (NHAPI) and in-
dividuals of non-Hispanic unknown race. Stage was coded according to
SEER summary stage (localized [T1−2N0M0] vs. regional [T3N0M0 or
TanyN1M0] vs. distant [T4NanyM0 or TanyNanyM1] vs. unknown
[TxNxMx]). Localized stage was further divided as T1aN0M0 vs.
T1bN0M0 vs. T2N0M0. Grade was coded according to the SEER four-
grade system from grade I, well- differentiated, which corresponds to
Fuhrman G1 to grade IV, undifferentiated or anaplastic, which corre-
sponds to Fuhrman G4 (G1 vs. G2 vs. G3 vs. G4 vs. GX). Histology was
coded as clear cell vs. non-clear cell (papillary, chromophobe, cyst-as-
sociated RCC, collecting duct and sarcomatoid) vs. non-specified (NOS).
Socioeconomic status was derived from an established combination of
median household income, percentage of population with at least a
high school education and percentage of population living 200 % below
poverty level and it was divided according to quartiles (1 quartile vs
2−3-4 quartiles).
2.2. Statistical analysis
Total counts and incidence rates were presented. Incidence rates per
100,000 person-years were age-adjusted and standardized to 2000
United States standard population (19 age groups, United States Bureau
of the Census, Current Population Reports, Publication 25–1130
[Census P25–1130]). Age-standardized rates (ASRs) represented
weighted averages of age-specific rates, where weights corresponded to
proportions of persons in each age group of a standard population.
Zero- knot Joinpoint regression model identified changes in trends.
Additionally, the average annual percent change (AAPC), which uses
the underlying Joinpoint model, computed a summary measure of the
trend over a pre-specified fixed interval (from 2000 to 2016) [12].
According to SEER reporting guidelines, ASRs were not reported for NH
unknown race, due to the low number of observations. Survival esti-
mates were based on the Kaplan Meier estimator. Specifically, Kaplan
Meier-derived five-year cancer-specific survival rates calculated for
cases diagnosed between 2000 and 2011 and reported for the overall
population, as well as for all planned stratifications.
All statistical tests were two-sided with a level of significance set at
p < 0.05. Analyses were performed using the R software environment
for statistical computing and graphics (version 3.4.1; http://www.r-
project.org/) and SEER*Stat (version 8.3.5; https://seer.cancer.gov/
seer stat/).
3. Results
3.1. Incidence and incidence trends
From 2000–2016, 7767 new RCC cases in young adults aged 20–39
years were recorded (Table 1). The average ASR was 0.6/100,000
person-years and significantly increased from 0.4/100,000 person-years
in 2000 to 0.8/100,000 person-years in 2016 (AAPC+5.0 %,
p < 0.001) (Fig. 1A).
Males (58.5 % of the cases) showed higher ASRs than females
(average ASRs 0.7/100,000 person-years vs. 0.5/100,000 person-years,
respectively). Incidence rates significantly increased over time in both
males (AAPC+5.0 %, p < 0.001) and females (AAPC+4.7 %
p < 0.001) (Fig. 1B).
After stratification according to ethnicity, NHW represented the
majority (56.7 %), followed by Hispanics (22.5 %), NHAA (13.0 %),
NHAPI (5.7 %) and NHAIAN (1.4 %). The ASRs were the highest in
NHAIAN (average ASR 1.0/100,000 person-years), followed by NHW
(ASR 0.6), NHAA (ASR 0.6), Hispanic (ASR 0.5) and NHAPI (ASR 0.3).
The ASRs significantly increased over time in all ethnic groups
(Fig. 1C).
After stratification according to stage, T1aN0M0 was the most fre-
quent stage (51.4 %), followed by T1bN0M0 (19.8 %), T2N0M0 (12.1
%), regional (8.6 %), distant (6.5 %) and unknown (1.5 %). The ASRs
were the highest for T1aN0M0 stage (average ASR 0.3/100,000 person-
years). A significant increase over time was recorded for T1aN0M0
(AAPC +5.2 %), T1bN0M0 (AAPC+5.7 %), T2N0M0 (AAPC+1.5
%) and regional stages (AAPC+3.7 %). Conversely, the ASR of distant
and unknown stages did not significantly change over time (Fig. 1D).
After stratification according to grade, G2 was most frequent grade
(44.4 %) and along with G1 (13.1 %) accounted for most RCCs. The
ASR of G2 was the highest (average ASR 0.3/100,000 person-years) and
significantly increased over time (AAPC+6.3 %, p=0.001).
Conversely, the ASR of G1 was the second lowest (average ASR 0.1/
100,000 person-years) and did not change over time. The ASRs of G3
and G4 grade increased over time (AAPC+6.0 and +8.3 %, respec-
tively), while the ASRs of GX grade remained stable (Fig. 1E).
After stratification according to histology, clear cell was most fre-
quent histology (54.8 %). The ASR of clear cell histology was the
highest (average ASR 0.3/100,000 person-years) and significantly in-
creased over time (AAPC+7.6 %, p < 0.001). Similarly, the ASR of
non-clear cell histology significantly increased over time (AAPC+6.9
%, p < 0.001). Conversely, the ASRs of NOS RCC remained stable over
time (Fig. 1F).
After stratification according to SES, the ASRs were the highest for
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the highest quartiles and increased to a similar extent for both the
lowest and highest quartiles (average ASR 0.1, AAPC+5.2 %,
p < 0.001 for 1-quartile vs. average ASR 0.4, AAPC+4.8 %,
p < 0.001 for 2−3-4 quartiles).
3.2. Renal cell carcinoma survival and survival trends
The average five-year cancer-specific survival rates were 89.9 % in
the overall cohort, 88.6 % in males and 91.6 % in females and sig-
nificantly increased over time (Table 2, Fig. 2A-B).
Stratification according to ethnicity (Fig. 2C) showed that NHW and
NHAA had respectively the highest (91.8 %) and lowest (81.7 %)
average five-year cancer-specific survival rates that significantly in-
creased in both ethnic groups over time. Conversely, five-year cancer-
specific survival rates did not change over time in NHAPI, NHAIAN and
Hispanics.
Stratification according to stage (Fig. 2D) showed that T1aN0M0
and T1bN0Mo stages were associated with highest five-year cancer-
specific survival rates (99.3 and 97.3 %, respectively). Nonetheless, no
significant changes over time in five-year cancer-specific survival rates
were recorded across all stages.
Stratification according to grade (Fig. 2E) showed that lower grade
was associated with better survival rates: 98.3 % in G1, 97.7 % in G2,
79.0 % in G3 and 45.1 % in G4. However, over time five-year cancer-
specific survival rates only significantly improved for G3 tumors.
Stratification according to histology (Fig. 2F) showed that clear cell
histology had the highest average five-year cancer-specific survival rate
(93.9 %). It was followed by non-clear cell histology with five-year
cancer-specific survival of 86.9 %. In both histological subtypes, the
five-year cancer-specific survival rates significantly increased over
time.
Stratification according to SES showed similar five-year cancer-
specific survival rates for both the lowest and highest quartiles that
marginally improved over time (91.4 %, AAPC +0.4, p= 0.1 for 1-
quartile vs. 89.3 %, AAPC+0.8, p < 0.001 for 2−3-4 quartiles).
4. Discussion
Few previous reports investigated cancer incidence trends in young
adults [3–5]. Moreover, these previous reports also focused on the
whole cancer spectrum, without providing the ability to focus on RCC.
In those reports [3–5], different age definition were used (15–39 years
[3] vs. 20–39 years [4] vs. 25–39 years[5]). However, regardless of age
definition, consistently low ASRs that were nonetheless increasing over
time [5] were reported. These omissions may mask important differ-
ences in RCC distribution in young adults. In consequence, we focused
on gender and race, as well as stage, grade and histology, in the most
contemporary version of the SEER database (2000–2016). We hy-
pothesized that young adults will be diagnosed at lowest stage and
grade. Moreover, we also hypothesized that potential differences may
exist according to ethnic groups. Our results showed several noteworthy
findings.
First, average RCC incidence rates in young adults were 0.6/
100,000 person-years and significantly increased from 2000 to 2016
(AAPC +5.0 %). Our results validate previous studies, where a sig-
nificant increase in RCC incidence in adolescent and young adults was
reported [3–5]. Additionally, the incidence rates in young adults are
much lower than those recorded for the general population [2,13–15],
where incidence rates ranged from 9.4 to 12.0/100,000 person-years.
These findings corroborate that RCC represents a rare entity in young
Table 1
Age-standardized incidence rates of renal cell carcinoma and corresponding average annual percentage changes in young adult patients (20-39 years-old), identified
within the Surveillance, Epidemiology, and End Results database from 2000 to 2016.
Age- standardized incidencea Time trends
No. patients (%) Average From (2000) To (2016) AAPC p
Overall 7767 (100) 0.6 0.4 0.8 +5.0 <0.001
Gender
Male 4547 (58.5) 0.7 0.4 0.9 +5.0 <0.001
Female 3220 (41.5) 0.5 0.3 0.6 +4.7 <0.001
Raceb
NHW 4386 (56.5) 0.6 0.4 0.9 +5.0 <0.001
NHAA 1007 (13.0) 0.6 0.6 0.7 +3.4 <0.001
NHAPI 441 (5.7) 0.3 0.2 0.4 +4.7 <0.001
NHAIAN 110 (1.4) 1.0 0.7 1.9 +5.5 0.02
Hispanic 1744 (22.5) 0.5 0.3 0.8 +6.4 <0.001
Stage
T1aN0M0 3995 (51.4) 0.3 0.1 0.4 +5.9 <0.001
T1bN0M0 1540 (19.8) 0.1 0.06 0.2 +5.7 <0.001
T2N0M0 938 (12.1) 0.07 0.07 0.08 +1.5 0.004
Regional 671 (8.6) 0.05 0.04 0.05 +3.7 0.001
Distant 505 (6.5) 0.04 0.03 0.05 +1.5 0.06
Unknown 118 (1.5) 0.01 0.01 0.01 +2.7 0.1
Grade
G1 1016 (13.1) 0.1 0.07 0.1 +1.1 0.2
G2 3451 (44.4) 0.3 0.1 0.4 +6.3 <0.001
G3 1325 (17.1) 0.1 0.04 0.1 +6.0 <0.001
G4 284 (3.7) 0.02 0.01 0.03 +8.3 <0.001
GX 1691 (21.8) 0.1 0.1 0.2 +2.4 0.06
Histology
Clear cell 4255 (54.8) 0.3 0.1 0.5 +7.6 <0.001
Non-clear cell 1548 (19.9) 0.1 0.01 0.2 +6.9 <0.001
NOS RCC 1875 (24.1) 0.1 0.2 0.1 −3.8 <0.001
Abbreviations. AAPC = average annual percentage changes; NHW = non-Hispanic White; NHAA = non-Hispanic African-American; NHAPI = non-Hispanic Asian
or Pacific Islander; NHAIAN = non-Hispanic American Indian/Alaska Native; NOS RCC = non-otherwise specified renal cell carcinoma.
a Age-standardized incidence rates are reported per 100,000 person/years and age-adjusted and standardized to 2000 United States Standard population (Census
P25–1130).
b Due to low numbers, the results of non-Hispanic unknown race were not reported, according to SEER reporting guidelines.
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adults, since its incidence is 50-fold lower than that of the general
population. However, although an increase in ASRs has been con-
sistently reported for the general population [13,16,17], the magnitude
of this increase seems to be inferior to the one reported in the current
study, as well as in previous analyses of young adults [5].
Second, to date only one large scale study addressed potential in-
cidence gender differences in incidence rates [4]. Specifically, world-
wide incidence rates were 0.7 vs. 0.5/100,000 person-years and ac-
counted for 2.2 % and 0.9 % of all new cancer diagnosis in young
adults, in respectively males and females. The current analyses confirm
a male predilection (0.7 vs 0.5/100,000 person-years). The higher ab-
solute value in males validates the effect of maleness, as a risk factor for
RCC in young adults. Nonetheless, virtually the same time trends were
recorded for both genders, with a similar increase in incidence rates
over time. Conversely, survival rates increased more in males
(AAPC+1.0 %) than in females (AAPC+0.4 %). Nonetheless, higher
absolute five-year cancer-specific survival rates were reported in fe-
males (91.6 vs. 88.6 %). These differences are in agreement with those
reported by Moke et al. [18], where female gender was associated with
lower mortality. These differences may be attributable to a more fa-
vorable stage and grade distribution in females, as previously described
[19].
Third, racial disparities in RCC incidence have not been examined in
young adults in the United States. Our analyses showed that NHAIAN
and NHAPI had respectively the highest and the lowest ASRs, while
Hispanics exhibited the highest increase over the study period. These
findings are similar to those recently reported for the general popula-
tion [16,17]. Additionally, average cancer-specific survival rates were
highest for NHW and lowest for NHAA. Nonetheless, NHW and NHAA
were the only two groups that exhibited a significant increase in
survival rates over time. It should be noted that for some groups, dif-
ferences in survival may be due to low number rather than real dif-
ference. These observations are in agreement with a previous study that
investigated overall mortality among adolescent and young adults [18].
Although, in this report race and ethnicity were not mutually exclusive
and the endpoint was overall rather than cancer-specific mortality,
these observations suggest that some ethnic groups may harbor more
renal cancers of more aggressive nature. Indeed, differences in well-
established risk factors prevalence, such as smoke and hypertension,
have been demonstrated across ethnic groups. For example, current
cigarette smoking has the highest prevalence among NHAIAN and the
lowest among NH Asian [20]. Higher rates of hypertension are recorded
within NHAA, compared to NHW, while Hispanics and NH Asian have
lower rates than both groups [21]. Finally, specific genetic and en-
vironmental factors may also play a prominent role in developing RCC
in different ethnic groups. These groups may represent prime targets for
further studies.
Fourth, T1aN0M0 RCC showed the highest ASR (0.3/100,000
person-years), as well as the highest increase over time (AAPC+5.9
%), followed by T1bN0M0 (AAPC+5.7 %). Nonetheless, also regional
and distant stages showed an increase over time (AAPC+3.7 %,
p=0.001 and AAPC+1.5 %, p= 0.06, respectively). These findings
are in agreement with Kehm et al. [5] that showed a significant increase
in both localized and, to a lesser extent, regional stages in patients aged
25–39 years from 1975 to 2015. Moreover, they are also in agreement
with data from the general population that showed highest ASRs for
localized stage [13,16]. These findings may be at least partially attri-
butable to the increasing use of cross-sectional imaging that leads to
early diagnosis, as we postulated. However, this may also imply over-
diagnosis with risk of potentially unnecessary treatments eventually
Fig. 1. Incidence and trends over time of renal cell carcinoma in young adults (20-39 years-old) in the United States from 2001 to 2016, displayed in the entire cohort
(A) and by gender (B), race (C), stage (D), grade (E) and histology (F).
Abbreviations. RCC renal cell carcinoma; ASRs age-standardized incidence rates; AAPC average annual percentage changes; NHW non- Hispanic White; NHAA non-
Hispanic African- American; NHAPI non-Hispanic Asian or Pacific Islander; NHAIAN non-Hispanic American Indian/Alaska Native; NOS non-otherwise specified.
Incidence rates were reported per 100,000 person/years and were age-adjusted and standardized to 2000 United States standard population (Census P25–1130).
Temporal trends were calculated through joinpoint regression analyses to describe the average annual percent change.
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leading to renal function impairment. Nonetheless, the significant in-
crease in T1bN0M0, T2N0M0 and regional stages incidence may also
suggest a real incidence RCC increase in young adults. Finally, survival
rates remained stable over time, showing very low rates of five-year
cancer specific mortality for T1aN0M0 and T1bN0M0.
Fifth, we are the first to report on incidence rates according grade
and histology. Here, we validate our hypothesis that most RCC are di-
agnosed at lower grade (G1-G2) and with clear cell histology. These
findings are encouraging, since grade is a well-known unfavorable
prognostic risk factor in RCC [22] and clear cell histology can be treated
with the largest spectrum of therapeutic measures that vastly exceed
those available for non-clear cell. However, we also recorded an in-
crease both higher grade (G3 or G4). The increase in non-clear cell
histology is difficult to interpret due to low counts and lack of ability to
further stratify non-clear cell histology patients according to specific
histological subgroups and stage. Nonetheless, we recorded an increase
in survival of G3 and non-clear cell tumors. These findings are highly
encouraging and may suggest that an increasing proportion of favorable
non-clear cell histology subtypes is diagnosed [23,24]. Nonetheless, this
increase may be attributable to a decrease overtime in assignment of
NOS RCC.
Sixth, the lowest SES quartile showed the lowest ASR, suggesting
that poorer people who eventually have limited access to medical care
may be underdiagnosed. Nonetheless, the similar incidence increased
over time in both the lowest and highest quartiles may also suggest that
socioeconomic factors and different access to medical care may not
explain at all the rising incidence of RCC.
Taken together, RCC incidence rates in young adults were low but
increased over time. This increase seems to be higher in young adults
relative to that reported in the entire population. Similar to the older
RCC patients, a male predilection was recorded. Differences in both
incidence and survival emerged across different ethnic groups that may
warrant further researches. Similar to older RCC patients, young adults
were predominantly diagnosed with localized stage, low grade tumors
or clear cell histology. Overall, five-year cancer-specific survival rates
were high and showed an increase over time. Our findings suggest that
despite the rarity of this disease, young adults seem to be promptly
investigated and diagnosis is not delayed. The increasing incidence in
young adults can be explained on the basis of ascertainment bias, due to
over-diagnosis of small renal masses. Nonetheless, increasing incidence
of higher stages, as well as similar increase in both the lowest and
highest SES quartiles, may also suggest that a real increase in RCC in-
cidence in young adults is occurring. Finally, further studies are needed
to assess health-care needs in survivors, that may face lifelong risks to
their physical, psychosocial, and financial health [25].
Our study is not devoid of limitations. First, our findings that relied
on the United States population may not be generalizable to other
Western countries. Second, although SEER relied on data-collecting
protocols, missing information on stage and grade, as well as non-
standardized histopathological review, may represent biases of the
current study. Third, misclassification in race and ethnicity may have
occurred. Furthermore, cancer rates for broad racial/ethnic groups such
as Hispanic and API may mask important variation by county of origin.
Additionally, low counts prevented us to further analyze stage dis-
tribution and trend over time within each ethnic group. Fourth, no
standardized specimen handling, as well as no central histological re-
view, was applied within the SEER database. Finally, it was not possible
to account for some well-recognized risk factors, such as smoking,
obesity and occupational exposure [26–29], since these data are not
available in the SEER database.
Table 2
Five-year cancer-specific survival rates of renal cell carcinoma and corresponding average annual percentage changes in young adult patients (20-39 years-old),
identified within the Surveillance, Epidemiology, and End Results database from 2000 to 2011.
Five-year cancer-specific survivala Time trends
Average From 2000 (95 % CI) To 2011 (95 % CI) AAPC p
Overall 89.9 86.2 (82.4−90.3) 91.5 (89.1−94.0) +0.7 <0.001
Gender
Males 88.6 84.9 (79.6−90.5) 90.3 (87.0−93.7) +1.0 <0.001
Females 91.6 88.0 (82.5−93.9) 93.5 (90.1−97.1) +0.4 0.04
Raceb
NHW 91.8 89.3 (84.8−93.9) 93.4 (90.4−96.4) +0.7 0.01
NHAA 81.7 73.8 (63.1−86.7) 89.7 (83.2−96.7) +2.2 <0.001
NHAPI 86.2 75.0 (54.1−100) 84.1 (73.7−96.7) +0.7 0.3
NHAIAN 90.4 100.0 (100−100) 80.0 (51.6−100) −0.7 0.6
Hispanic 90.8 90.5 (82.1−99.8) 91.3 (86.0−96.9) +0.08 0.7
Stage
T1aN0M0 99.3 98.3 (95.9−100) 99.2 (98.1−100) +0.1 0.2
T1bN0M0 97.3 95.6 (89.8−100) 96.8 (93.3−100) +0.2 0.4
T2N0M0 94.8 92.8 (86.3−99.8) 96.3 (99.8−100) +0.4 0.2
Regional 73.9 73.6 (60.8−89.1) 61.5 (48.0−78.8) −0.1 0.9
Distant 16.4 25.5 (13.3−48.6) 11.4 (3.1−41.2) −1.0 0.8
Unknown 83.2 83.3 (58.2−100) 85.7 (63.3−100) +0.3 0.9
Grade
G1 98.3 100.0 (100−100) 98.0 (94.2−100) +0.1 0.4
G2 97.7 95.3 (91.3−99.4) 99.1 (99.4−100) +0.2 0.05
G3 79.0 61.1 (47.1−79.3) 84.7 (77.3−92.7) +3.2 0.01
G4 45.0 50.0 (22.5−100) 43.5 (27.3−69.3) +3.4 0.2
GX 81.6 80.0 (72.1−79.7) 86.5 (79.7−93.9) +0.5 0.3
Histology
Clear cell 93.9 90.8 (84.9−97.1) 95.5 (93.1−97.9) +0.5 0.01
Non-clear cell 86.9 83.3 (58.3−100) 89.6 (83.7−95.9) +0.9 0.01
NOS RCC 84.7 84.3 (79.3−89.5) 82.1 (74.8−89.9) +0.1 0.6
Abbreviations. CI= confidence intervals; AAPC = average annual percentage changes; NHW = non-Hispanic White; NHAA = non- Hispanic African-American;
NHAPI = non-Hispanic Asian or Pacific Islander; NHAIAN = non-Hispanic American Indian/Alaska Native; NOS RCC = non- otherwise specified renal cell car-
cinoma.
a Kaplan Meir-derived five-year cancer-specific survival rates. Temporal trends were calculated through joinpoint regression analyses to describe the average
annual percent change.
b Due to low numbers, the results of non-Hispanic unknown race were not reported, according to SEER reporting guidelines.
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5. Conclusions
RCC in young adults is rare, but increasing. This is mainly due to
T1aN0M0 tumors. Nonetheless, also regional diseases are significantly
increasing. Differences between ethnic groups exist and may warrant
further research.
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